November 2–4 | Shanghai

Dr. Jue Wang, Head of Global Business Development at Insilico Medicine, has been invited to attend the China Healthcare Summit in Shanghai. On the afternoon of November 3 at 16:45, she will deliver a keynote speech in the panel titled: “The Commoditization Trap: Who Wins When Everyone Has the Same Ai?“

As generative AI tools become commoditized and model capabilities increasingly turn into “public infrastructure,” true differentiation no longer lies in whether one has AI, but in how seamlessly AI is integrated into a full closed-loop workflow—from target discovery and molecular generation to clinical validation. Drawing on Insilico Medicine’s engineering practices and external partnerships with the Pharma.AI platform, Dr. Wang will share her perspectives on the competitive landscape in the “era of AI commoditization.” She will highlight that data assets, automated experimental feedback loops, expert models, and tangible pipeline deliverables are the true keys to overcoming the commoditization trap. As Head of Global Business Development, she will also provide front-line insights into cross-border transactions and partnering models in AI-driven drug discovery.

About the China Healthcare Summit

Jointly hosted by BioCentury, BayHelix, and McKinsey & Company, the China Healthcare Summit has been held annually in Shanghai for more than a decade. It stands as one of the most influential international dialogue platforms in China’s biopharmaceutical sector, as well as a prime venue for multinational pharmaceutical BD&L executives and investors seeking Chinese innovative assets. Covering licensing transactions, NewCo models, regulatory evolution, capital flows, market access strategies, and emerging Asian market opportunities (such as South Korea and Singapore), the summit serves as a vital window into China’s life sciences ecosystem and the evolving global biopharma landscape

November 4–5 | Shanghai

Dr. Feng Ren, Co-CEO and Chief Scientific Officer of Insilico Medicine, has been invited to attend the 2026 Future Healthcare Investment Market (FHIM) annual conference at the Shanghai International Convention Center, where he will deliver a keynote address on the afternoon of November 4.

Focusing on AI-driven small molecule R&D practices, Dr. Ren will discuss how generative chemistry coupled with automated experimental loops significantly accelerates the journey from target to preclinical candidate (PCC). Drawing on several of Insilico’s clinical-stage in-house programs, he will illustrate how AI platforms translate “technological advantages” into sustainable pipeline assets and transactable value propositions. Amid a more prudent global capital environment, he will also share actionable perspectives on how innovative drug developers can unlock and realize value through technological differentiation and business development partnerships.

About the 2026 Future Healthcare Investment Market (FHIM)

The Future Healthcare Investment Market is a premier industry gathering dedicated to bridging Chinese pharmaceutical innovation with global capital. Held on November 4–5 at the Shanghai International Convention Center, the conference convenes leading life sciences investment firms from Europe and China, multinational pharma BD leaders, and innovative biotech founders. Key topics include cross-border out-licensing and co-development of innovative drug assets, valuation frameworks for emerging technology platforms, and substantive deal-making facilitated through keynote speeches, panel discussions, and one-on-one partnering meetings.

November 5-10 | Shanghai

Insilico Medicine has once again been invited to exhibit at the China International Import Expo (CIIE), located at Booth C1-01, Hall 2.2. For this edition, Insilico is debuting holographic projection technology to present its R&D pipeline in three dimensions, intuitively deconstructing cutting-edge disease targets and innovative drug molecular conformations for an immersive, interactive tech experience.

Behind these booth highlights lies Insilico Medicine’s robust pipeline momentum and platform translational capability. To date, within the first 10 months of 2026 alone, the company has nominated 11 preclinical candidates (PCCs)—setting a new historic annual record and bringing the cumulative total since 2021 to 35 PCCs. This track record demonstrates the breakthrough efficiency of generative AI through reproducible, real-world R&D outputs. Furthermore, as disclosed in the 2026 interim report, Insilico achieved 8 clinical milestones across its internal and partnered pipelines as of mid-August.

Among its numerous pipeline advances, Rentosertib (ISM001-055)—the world’s first fully generative AI-discovered drug candidate with first-in-class potential—has officially entered Phase III clinical trials for idiopathic pulmonary fibrosis (IPF), marking a critical milestone in the final sprint toward definitive clinical benefit and commercialization.

About the 9th China International Import Expo (CIIE)

Co-hosted by the Ministry of Commerce of the People’s Republic of China and the Shanghai Municipal People’s Government, and organized by the China International Import Expo Bureau and the National Exhibition and Convention Center (Shanghai), CIIE partners with international bodies including the WTO, UNIDO, and ITC. It represents a major national initiative to proactively open China’s market to the world. The 9th CIIE will take place from November 5 to 10, 2026, at the National Exhibition and Convention Center (Shanghai), covering an exhibition area of over 300,000 square meters. It features six major exhibition areas—Medical Equipment & Healthcare Products, Automobiles & Smart Mobility, Intelligent Industry & Information Technology, Consumer Goods, Food & Agricultural Products, and Trade in Services—alongside an Innovation Incubation Special Section, with the Hongqiao International Economic Forum held concurrently. The Medical Equipment & Healthcare Products exhibition area (Halls 1.1H, 1.2H, and 2.1H) introduces world-leading medical innovations, cutting-edge technologies, and services to support the Healthy China initiative and the silver economy.

November 6-8 | Nanchang

Dr. Feng Ren, Co-CEO and Chief Scientific Officer of Insilico Medicine, has been invited to attend the 2026 Chinese Pharmaceutical Association Medicinal Chemistry Symposium (CMCS2026) in Nanchang. On the morning of November 7 at 11:00 AM, he will deliver a presentation titled: “Generative AI-Driven Innovative Drug Discovery and Clinical Advances.”

From target discovery to molecular design and clinical-stage candidates, generative AI is reshaping the paradigm of medicinal chemistry. Dr. Ren will systematically elaborate on how Insilico Medicine leverages platforms such as PandaOmics and Chemistry42 to construct an end-to-end closed loop spanning target identification, de novo molecular generation, and automated experimental validation. He will also showcase the latest clinical progress of several AI-discovered targets and AI-designed molecules, exploring the essential hurdles generative AI must clear to transition from an “efficiency tool” to an “engine of original innovation,” offering a front-line industry case study on the convergence of medicinal chemistry and artificial intelligence.

November 7–10 | Dubai

Dr. Alex Aliper, Co-Founder and President of Insilico Medicine, has been invited to attend the Next Generation Medicine Congress 2026 in Dubai. On the afternoon of November 7 at 5:00 PM, he will speak on a panel titled: “INVESTOR AND INNOVATOR PANEL.”

During this direct dialogue between capital and technology, Dr. Aliper will draw upon an AI biotech’s trajectory from technical proof-of-concept to a scaled pipeline, sharing how innovators can demonstrate enduring “platform capabilities” to investors rather than relying on a single narrative: reproducible wet-lab closed loops, consistently delivered clinical milestones, and an expanding partnership footprint together form the authentic competitive moat of an AI biotech company.

About the Next Generation Medicine Congress 2026

The Next Generation Medicine Congress is a premier international forum focused on translating cutting-edge medicine from evidence to real-world application. Taking place from November 7 to 10 in Dubai, the event convenes over 60 speakers and executive leaders from more than 20 countries across regenerative medicine, longevity medicine, precision healthcare, and healthcare investment. Under the theme “From Evidence to Adoption — Building the Clinic of 2030 Today,” the congress explores clinical translation pathways, medical technology adoption frameworks, and healthcare investment trends, featuring a dedicated Investor and Innovator Panel to bridge the “last mile” from frontier medical breakthroughs to clinical and commercial realization.

About Insilico Medicine

Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend healthy longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK.

By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine.

Full Story

“Upon completion, this will be invaluable for rapidly advancing our understanding and preventing debilitating co-occurring conditions in DS”

Boston University Chobanian & Avedisian School of Medicine researchers Tarik F. Haydar, PhD, the Waterhouse Chair and Professor of anatomy & neurobiology, along with Nobuyuki Ishibashi, MD, a professor in the same department, have recently been awarded a two-year, ~$450,000 grant from the National Institutes of Health for their project “A Trisomic Porcine Model of Studying Down Syndrome in the Gyrencephalic Brain.”

Full Story

Targeting cellular pathways controlled by norrin can be used as a therapeutic strategy to prevent vision loss in patients with diabetes

Over 100 million people in the U.S. are affected by diabetic retinopathy, a complication of diabetes that affects the eyes. The condition is caused by damage to the blood vessels in the retina, the light sensitive tissue at the back of the eye. At first, diabetic retinopathy might not cause any symptoms, or the problems might be mild. However, if the underlying diabetes remains poorly managed, it can lead to blindness. In a new study, University of Michigan researchers showed that treatment with the molecule norrin can prevent vision loss in diabetic rats.  

Diabetic Retinopathy Treatment 

Current therapies for diabetic retinopathy target vascular endothelial growth factor, or VEGF, a protein that causes new blood vessels to form. VEGF also increases blood vessel permeability or the capacity to allow water and nutrients to move in and out of the bloodstream into tissues. In patients with diabetic retinopathy, excess VEGF causes the growth of abnormal, leaky blood vessels, both leading to vision loss.  

Full Story

New results strengthen the foundation for commercial naïve exosome supply and continued development of ExoPTEN

On October 30, 2026, NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) announced new laboratory results demonstrating consistent anti-inflammatory activity across three batches of its naïve exosomes, supporting both its developing commercial supply business through Exo-Top Inc. (“Exo-Top”) and continued development of its lead therapeutic candidate, ExoPTEN.

Anti-inflammatory activity is a key biological property attracting interest in exosomes for applications ranging from skin health to tissue repair. NurExone’s latest results showed that three separately produced batches demonstrated similar and substantial anti-inflammatory activity. Two key proteins involved in inflammation, IL-6 and TNF-α, showed average reductions of approximately 88% and 57%, respectively. This anti-inflammatory activity shown in the laboratory supports the potential of NurExone’s exosomes for clinical applications where controlling inflammation is relevant to tissue protection, repair, and regeneration.

Full Story

Results published in PNAS show that space-grown organoids more closely resemble human glioblastoma tumors than those grown on Earth

Glioblastoma (GBM) is the most common malignant primary brain tumor in adults and is one of the most aggressive and deadly forms of cancer. It is difficult for surgeons to fully remove GBM because it often has microscopic “tentacles” that extend from the tumor into healthy brain tissue. GBM is also hard to treat because it creates an immunosuppressive microenvironment that helps the cancer evade immune attack and resist therapy. To improve treatments, scientists must better understand the mechanisms involved in this complex disease, but accurately modeling GBM in the laboratory remains a challenge. Even sophisticated models called organoids, designed to mimic the structure and biology of human tumors, fail to fully reproduce key features of advanced GBM. When culturing cells on Earth, gravity causes them to settle, creating conditions that can interfere with the formation of complex 3D structures. That is why a team of researchers at the University of Notre Dame, led by Meenal Datta, PhD, took their research to space.

Full Story

On October 27, 2026, PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced that management will be participating in the following upcoming investor conferences:

• Monday, November 9, 2026: UBS Global Healthcare Conference in Palm Beach Gardens, FL. Management will participate in a fireside chat at 5:00PM ET.
• Monday, November 16, 2026: Jefferies Global Healthcare Conference in London, UK. Management will participate in 1×1 investor meetings.
• Wednesday, November 18, 2026: Stephens NASH26 Conference in Nashville, TN. Management will participate in a fireside chat at 3:45pm ET.

Live webcasts of the fireside chats can be accessed at the company’s investors page at investor.pacificbiosciences.com. A replay of each webcast will be available for at least 30 days following the event.

Full Story

The American Association of Extracellular Vesicles (AAEV) invites you to attend the organization’s annual meeting November 12-15 in the New York City area. This year’s meeting will feature more than 30 invited speakers from leading institutions, covering the latest advances in extracellular vesicles, translational research, therapeutics, and diagnostics. The program is available now. You may register here (https://www.aaev.org/aaev2026-registration).

Full Story

On October 27, 2026, 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, announced that members of its management team will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in London on Tuesday, November 17, at 4:30 p.m. Greenwich Mean Time. Interested parties may access a live webcast of the fireside chat on the “Investors” section of the company’s website at: https://investors.10xgenomics.com/. The webcast will be archived and available for replay for at least 30 days after the event.

Full Story

A leader in research on obstetric complications and the prevention of preterm birth recognized for her groundbreaking contributions to maternal-fetal health

On October 21, 2026, UC San Diego announced that Cynthia Gyamfi-Bannerman, MD, MS, professor and chair of the Department of Obstetrics, Gynecology, and Reproductive Sciences and Samuel S.C. Yen Endowed Chair at University of California San Diego School of Medicine, has been elected to the National Academy of Medicine (NAM). Election to the National Academy of Medicine is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated outstanding professional achievement and commitment to service. New members are elected by current members through a process that recognizes individuals who have made major contributions to the advancement of the medical sciences, health care, and public health, and inspires positive actions across sectors. Recognized as an international leader in maternal-fetal medicine, Gyamfi-Bannerman was elected for her pioneering landmark clinical trials that expanded the use of antenatal corticosteroids to improve respiratory outcomes for infants born late preterm and changing obstetric practice internationally. The follow-up studies provided novel insights on hypoglycemia, neurodevelopment, and growth in children born late preterm.

Full Story

A study led by Oxford University has found that seabirds flying long distances across the Atlantic can experience a mismatch between their internal body clocks and local time (the same process which leads to jet lag in humans), causing them to make predictable errors when navigating by the sun. The results were published October 29, 2026 in the journal Science. The article is titled “Rapid Longitudinal Flights Cause Time Shifts and Sun Compass Error.” Many animals, including birds, use the sun to find their way. But because the sun moves across the sky throughout the day, they need an accurate internal clock to interpret its position correctly. Normally, birds reset their internal clocks using sunrise as a cue. However, when they travel rapidly east or west during the day, their internal clocks may temporarily become out of sync with local solar time. This could cause them to misjudge the sun’s position and fly slightly off course.

Full Story